Amgen stock trades near a yearly high after Q2 beats
Published on 08/12/2026 at 14:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock stayed close to a 1-year high after the company reported Q2 2026 results on 4 August 2026, with adjusted EPS of $6.29 and revenue of $10.05 billion. The latest market data put Amgen at about $414.30 on 11 August 2026, alongside a market capitalization of roughly $223.98 billion, according to a MarketBeat report.
EPS beats by $0.67
The earnings release on 4 August 2026 said non-GAAP EPS of $6.29 beat the consensus estimate of $5.62 by $0.67. Revenue also came in above the $9.43 billion estimate, a gap of $620 million, while sales rose 9.5% year over year from the same quarter in 2025, according to the same release on Amgen's investor site.
That combination matters because Amgen is now showing both margin support and top-line growth in the same quarter. MarketBeat's 11 August 2026 coverage also showed a hold consensus and an average price target of $371.68, placing the stock above that level in the latest quote snapshot.
Guidance moves higher
Amgen lifted its FY 2026 non-GAAP EPS guidance to $22.30 to $23.50 in the 4 August 2026 release, while revenue guidance stood at $38.2 billion to $39.4 billion in the transcript cited by the earnings call transcript. The same transcript said management now expects other revenue of about $1.9 billion for 2026, a detail that helps explain why full-year profit guidance moved higher.
The dividend adds another dated marker. Amgen said on 30 July 2026 that it will pay a quarterly dividend of $2.52 per share, equal to $10.08 annualized, with the ex-dividend date set for 21 August 2026.
Repatha gets broader use
Beyond the quarter, Amgen's pipeline also had a product-specific catalyst on 29 July 2026, when the company said a positive CHMP opinion supported broader use of Repatha before a first heart attack or stroke. That matters for investors because Repatha remains one of the company's best-known growth products, and the regulatory step could widen the addressable population in Europe.
Amgen's investor page lists the 2026 third-quarter dividend announcement, the 4 August 2026 earnings release, and the 29 July 2026 Repatha update as the latest company news. Those dates show a dense sequence of report, capital-return, and product news within two weeks, which is what the market has been digesting around the stock.
Repatha in Europe
Repatha is the clearest product reference point in the latest company news flow, because the 29 July 2026 CHMP opinion directly touched a major cardiovascular therapy. For Amgen, the product note is brief but relevant: it links a named asset to a concrete regulatory step and sits next to the quarter's earnings and guidance update.
Shares near $414.30
Amgen shares were quoted around $414.30 on 11 August 2026, according to MarketBeat's latest snapshot, with a market capitalization near $223.98 billion. That price sat well above the average target of $371.68 shown in the same source, while the company itself had already pointed to FY 2026 EPS of $22.30 to $23.50.
Amgen at a glance
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: NASDAQ: AMGN
- Trading venue: NASDAQ
- Price (as of 11 August 2026, 16:00 ET): $414.30 USD
- Market capitalization: $223.98 billion USD (as of 11 August 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: S&P 500
